Venturi Wealth Management LLC Invests $271,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Venturi Wealth Management LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,000 shares of the biopharmaceutical company’s stock, valued at approximately $271,000.

A number of other large investors also recently added to or reduced their stakes in the business. State Street Corp boosted its position in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Principal Financial Group Inc. lifted its stake in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares in the last quarter. Castellan Group bought a new position in shares of TG Therapeutics during the 4th quarter valued at about $8,539,000. Public Sector Pension Investment Board purchased a new position in shares of TG Therapeutics during the third quarter valued at about $6,619,000. Finally, JPMorgan Chase & Co. grew its position in shares of TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after purchasing an additional 270,286 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $30.94 on Friday. The firm has a market capitalization of $4.82 billion, a PE ratio of -309.37 and a beta of 2.26. The stock’s fifty day moving average is $31.09 and its 200 day moving average is $27.64. TG Therapeutics, Inc. has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TGTX shares. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, StockNews.com cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.